

510(k) SUMMARY

CAIS Staple

Submitter's Name and Address:

DePuy Mitek, a Johnson & Johnson company
325 Paramount Drive
Raynham, MA 02767

Contact Person

Ruth C. Forstadt
Project Manager, Regulatory Affairs
DePuy Mitek, a Johnson & Johnson company
325 Paramount Drive
Raynham, MA 02767
Telephone: 508-977-3988
Facsimile: 508-828-3750
e-mail: rforstad@dpyus.jnj.com

Name of Medical Device

Proprietary Name: CAIS Staple

Substantial Equivalence

CAIS Staple is substantially equivalent to: PDS/PGA Staple (K021953)

Device Classification

Classification Name: Single/multiple component metallic bone
fixation appliances and accessories
(21 CFR 888.3030), Product code: 87 JDR

Common/Usual Name: Staple, fixation, bone

Device Description

The CAIS Staple is a PDS implant that attaches a scaffold to articular cartilage lesions in the knee.

Indications for Use

The CAIS Staple is an absorbable implant used in the fixation of periosteal autograft to articular cartilage lesions of the knee.

Safety and Performance

Results of performance and safety testing have demonstrated that the modified device is substantially equivalent to the predicate devices.

Based on the indications for use, technological characteristics, and comparison to predicate devices, the CAIS Staple has been shown to be substantially equivalent to predicate devices under the Federal Food, Drug and Cosmetic Act.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

DePuy Mitek
a Johnson & Johnson Company
% Ms. Ruth C. Forstadt
325 Paramount Drive
Raynham, MA 02767

MAY - 2 2008

Re: K073281
Trade/Device Name: CAIS Staple
Regulation Number: 21 CFR 888.3030
Regulation Name: Single/multiple component metallic bone fixation
appliances and accessories
Regulatory Class: Class II
Product Code: JDR
Dated: April 2, 2008
Received: April 3, 2008

Dear Ms. Forstadt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson", with a long horizontal flourish extending to the right.

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number (if known): 16073281

Device Name: CAIS Staple

The CAIS Staple is an absorbable implant used in the fixation of periosteal autograft to articular cartilage lesions of the knee.


Prescription Use ✓
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 of



(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number 16073281